Online inquiry

IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3497MR)

This product GTTS-WQ3497MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3497MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ952MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-323
GTTS-WQ9448MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IPH4102
GTTS-WQ3767MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ7853MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ12748MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ1531MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ8762MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ1609MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACE-536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW